デンマークのNovo Holdingsが165億ドルで 製薬会社Catalentの買収を完了した. Danish firm Novo Holdings completes $16.5B acquisition of pharmaceutical company Catalent.

デンマークの投資会社Novo Holdingsは,大手製薬会社であるCatalent Inc.の165億ドル買収を完了しました. Novo Holdings, a Danish investment firm, has completed its $16.5 billion acquisition of Catalent Inc., a major pharmaceutical manufacturing company. Catalentの株主は,当該株の2月終了価額の16.5%を超え,1株あたり6.3.50ドルを受給する. Catalent’s stockholders will receive $63.50 per share in cash, marking a 16.5% premium over the stock's February closing price. 現在私有企業となったカタレントは,さらに3つの製造拠点を獲得し,医薬品サービスの強化を図る. Catalent, now a private company, will also gain three additional manufacturing sites, enhancing its pharmaceutical services.